NR3C1 and lymphoma: 4-(1-hydroxy-2-(piperidin-1-yl)ethyl)phenol, or CpdA-03, demonstrated superior GR affinity and stability compared to CpdA as well as anti-lymphoma properties both in vitro and in vivo [17].